Justin Call, MD
Medical Oncology · West Jordan, UTNPI 1124172697
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by Cornerstone Specialty Network LLC at 27.0% of the total. Reporting peaked in 2023 at $21,119 and has fallen 73.9% since, to $5,510 in 2025. Among medical oncology clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 282 payments — averaging $377.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cornerstone Specialty Network LLC$29K
- Daiichi Sankyo Inc.$12K
- AstraZeneca$11K
- Pfizer$9K
- Gilead$6K
- Blueprint Medicines Corporation$5K
- plus $34K from 34 others
Across 1,037 payments — averaging $7848.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alkermes, Inc.$1.6M
- Genmab U.S., Inc.$1.6M
- Seagen Inc.$1.4M
- Pfizer$1.1M
- Janssen Research & Development, LLC$499K
- Eli Lilly$489K
- plus $1.4M from 14 others
What the payments were for
- Consulting fees$48,16745%
- Speaking & faculty fees$50,21047%
- Travel & lodging$4,4044%
- Food & beverage$3,3663%
- Education$2930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$106,440 in reported general payments places this provider in the 90th percentile of 43 medical oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisone | 22 | $78 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in West Jordan
- Bradley HunterSalt Lake City$263K
- William NibleyMurray$160K
- David GillMurray$129K
- Gregory LittonMurray$99K
- Robert HavardSalt Lake City$57K
- Wallace AkerleySalt Lake City$38K
- Ignacio Garrido-LagunaSalt Lake City$35K
- Mei WeiSalt Lake City$34K
- Xylina GreggSalt Lake City$31K
- Paul ShamiSalt Lake City$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.